{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.43","upperLimit":"10.56","value":"5.47"},{"groupId":"OG001","lowerLimit":"2.71","upperLimit":"8.98","value":"5.70"},{"groupId":"OG002","lowerLimit":"2.78","upperLimit":"8.79","value":"5.70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"41"}],"units":"Participants"}],"description":"Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis.","dispersionType":"Full Range","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG002","title":"High-Risk Group"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who received methotrexate during induction cycle 2 and had samples collected for PK analysis.","reportingStatus":"POSTED","timeFrame":"Pre-infusion and 6, 23, 42, 66 hours from start of MTX","title":"Methotrexate Clearance in Induction Cycle 2","type":"SECONDARY","unitOfMeasure":"L/h/m^2"}